Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer

• DOI: 10.1200/jco.2004.01.127
• Publication Date: 2004-08-17T01:08:46Z
• Authors: Michael R. Bishop; Daniel H. Fowler; Donna Marchigiani; Kathleen Castro; Claude Kasten-Spo...; Seth M. Steinberg; Juan C. Gea-Banac...; Robert Dean; Catherine K. Chow; Charles Carter; Elizabeth J. Read; Susan Leitman; Ronald Gress
• Keywords: Immunosuppression

Allogeneic T lymphocytes can induce regression of metastatic breast cancer through an immune-mediated graft-versus-tumor (GVT) effect in murine models. To determine if a clinical GVT exists against cancer, allogeneic were used as adoptive cellular therapy after reduced-intensity chemotherapy conditioning regimen and hematopoietic stem-cell transplantation (HSCT) from human leukocyte antigen-matched siblings.Sixteen patients with that had progressed treatment anthracyclines, taxanes, hormonal agents, trastuzumab, received HSCT. The transplant consisted cyclophosphamide fludarabine. distinguish immunological any antitumor cytotoxic the transplant-conditioning regimen, removed graft subsequently administered late postallogeneic containing 1 x 10(6), 5 10 10(6) CD3(+) cells/kg infused on days +42, +70, +98 post-allogeneic HSCT, respectively.Objective tumor regressions occurred day +28 HSCT six attributed to lymphocyte infusions. Two these responding disease progression before subsequent regression. Tumor concomitantly establishment complete donor T-lymphoid engraftment, associated development graft-versus-host (GVHD), abrogated by systemic immunosuppression for GVHD.Allogeneic advanced cancer. These results indicate provide rationale further this largely incurable disease.